Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Novartis Pharmaceuticals

Clinicaltrial registered10 Nov 2026

Novartis Pharmaceuticals

10 Nov 2026: Trial registered · A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
10 Nov 2026
Title
A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic Castration Resistant Prostate Cancer Patients
Conditions
Metastatic Castration-Resistant Prostate Cancer
Study Type
Observational
Status
Not Yet Recruiting
Reference
NCT07928037
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Novartis Pharmaceuticals

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Novartis Pharmaceuticals in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.